Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease

Takahito Moriyama, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Hidekazu Sugiura, Takashi Takei, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Background Blockade of the renin-angiotensin- aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown. Materials and methods We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment. Results Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change. Conclusions Aliskiren combined with olmesartan reduces proteinuria in CKD patients.

Original languageEnglish (US)
Pages (from-to)841-845
Number of pages5
JournalInternational Urology and Nephrology
Volume44
Issue number3
DOIs
StatePublished - Jun 1 2012

Keywords

  • Aliskiren
  • Chronic kidney disease
  • Olmesartan
  • Proteinuria

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint

Dive into the research topics of 'Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease'. Together they form a unique fingerprint.

Cite this